Literature DB >> 2971725

IgE receptor on human lymphocytes. IV. Further analysis of its structure and of the role of N-linked carbohydrates.

M Letellier1, T Nakajima, G Delespesse.   

Abstract

Previous studies have shown that the low affinity receptor for IgE (Fc epsilon R II) on human B lymphocytes was comprised of three components with apparent Mr of 45, 65 to 95, and 37 kDa. The present results indicate that the 37-kDa component is a soluble degradation fragment of the 45-kDa component and they also suggest that the 65- to 95-kDa component is probably made of aggregates of the above components that are formed after solubilization of the cells. The 45-kDa component appears to be a glycoprotein containing several sialic acid residues, O-linked carbohydrates and one N-linked carbohydrate chain that is of the complex type. Partial digestion of the purified 65- to 95-, 45-, and 37-kDa molecules with alpha-chymotrypsin or protease V8 generates several fragments with identical mobility on SDS-PAGE. The 37 kDa is not N-glycosylated but like the IgE-binding factors present in the culture supernatant of Fc epsilon R-bearing cells, it contains sialic acid and O-linked carbohydrates. On incubation with protease inhibitors, the Mr of IgE-binding factors (BF) is shifted from 25-27 to 37 kDa, indicating that IgE-BF are derived from the proteolytic cleavage of the 37-kDa molecule, previously identified as a membrane component of Fc epsilon R. On incubation with N-glycosylation inhibitors, the production of IgE-BF is significantly increased indicating that N-glycosylation inhibits the degradation of Fc epsilon R into IgE-BF. Inasmuch as the effect of glycosylation inhibitors is not prevented by monensin, it is concluded that all the IgE-BF are derived from surface Fc epsilon R and not from their intracellular precursors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971725

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Partial characterization of natural and recombinant human soluble CD23.

Authors:  K Rose; G Turcatti; P Graber; S Pochon; P O Regamey; K U Jansen; E Magnenat; N Aubonney; J Y Bonnefoy
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

2.  Phenotyping of peripheral blood lymphocytes in adult coeliac disease.

Authors:  A Di Sabatino; E Bertrandi; M Casadei Maldini; F Pennese; F Proietti; G R Corazza
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

Review 3.  The receptor for the Fc region of IgE.

Authors:  A D Keegan; D H Conrad
Journal:  Springer Semin Immunopathol       Date:  1990

4.  Native and recombinant soluble CD23 fragments with IgE suppressive activity.

Authors:  M Sarfati; B Bettler; M Letellier; S Fournier; M Rubio-Trujillo; H Hofstetter; G Delespesse
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

5.  Mechanism of formation of human IgE-binding factors (soluble CD23): III. Evidence for a receptor (Fc epsilon RII)-associated proteolytic activity.

Authors:  M Letellier; T Nakajima; G Pulido-Cejudo; H Hofstetter; G Delespesse
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

6.  Cytokine effects of CD23 are mediated by an epitope distinct from the IgE binding site.

Authors:  M D Mossalayi; M Arock; G Delespesse; H Hofstetter; B Bettler; A H Dalloul; E Kilchherr; F Quaaz; P Debré; M Sarfati
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

7.  Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions.

Authors:  J V Ravetch; B Perussia
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.